I-Mab Gets Boost from Latest Industry Signals on New Cancer Treatment

Company’s shares surged as much as 15% after AstraZeneca unveiled upbeat results for a new class of cancer drugs known as CD73 antibodies Key Takeaways: I-Mab’s shares surged up to 15% on positive results from a peer developing a similar new type of cancer treatment, though they later gave back most of those gains Company has plenty of cash on hand, and could soon get more as it seeks a deal to commercialize the drug, uliledlimab, with a U.S. or European partner By Doug Young It may still be at…

Read MORE »